Catalent Inc (NYSE:CTLT) has received an average rating of “Buy” from the ten ratings firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and eight have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $54.17.
A number of equities analysts have recently issued reports on CTLT shares. Jefferies Financial Group raised Catalent from a “hold” rating to a “buy” rating and increased their target price for the stock from $50.00 to $62.00 in a research note on Friday, June 21st. Zacks Investment Research downgraded Catalent from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. Finally, UBS Group raised their price objective on Catalent to $64.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd.
In other news, insider Barry Littlejohns sold 15,940 shares of the business’s stock in a transaction on Friday, July 12th. The shares were sold at an average price of $53.53, for a total transaction of $853,268.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Steven L. Fasman sold 4,053 shares of the business’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $54.04, for a total transaction of $219,024.12. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.
NYSE:CTLT traded up $0.57 on Tuesday, reaching $55.84. The company’s stock had a trading volume of 499,100 shares, compared to its average volume of 643,577. Catalent has a 12-month low of $29.23 and a 12-month high of $58.38. The company has a quick ratio of 1.71, a current ratio of 2.18 and a debt-to-equity ratio of 1.31. The firm has a market cap of $8.05 billion, a price-to-earnings ratio of 35.12, a price-to-earnings-growth ratio of 2.72 and a beta of 1.64. The stock has a 50 day moving average price of $55.31 and a 200 day moving average price of $46.82.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Recommended Story: What is intrinsic value?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.